ACB Trent, Northern & Yorkshire Virtual Event - Current and Future Horizons for Lipids in North East England and Beyond
ACB Trent, Northern & Yorkshire Virtual Event - Current and Future Horizons for Lipids in North East England and Beyond
This event is now fully booked.
You may join the waiting list. We shall contact all registered delegates in the lead up to the event and if any wish to cancel then their places will be offered to those on the waiting list.
Morning Session: Chair - Dr Ahai Luvai, Newcastle upon Tyne Hospitals
0955 – 1000 Introduction
Dr Ahai Luvai, Newcastle upon Tyne Hospitals
1000 – 1030 Recent developments in FH genetic testing
Dr Ciaron McAnulty, Northern Genetics Service
1030 - 1100 Optimising the diagnosis of FH using bioinformatics
Rachel O’Leary, NICE external assessment centre
1100 - 1120 Advances in PCSK9i provision in the North East
Dr Purba Banerjee, Newcastle upon Tyne Hospitals
1120 – 1130 Break
1130 – 1200 ApoB and β-quantification in the investigation of hypertriglyceridaemia
Dr Chris Boot, Newcastle upon Tyne Hospitals
1200 – 1230 An assay for atorvastatin: pitfalls and an unexpected surprise
Dr Liz Robinson, Northumbria NHS Foundation Trust
1230- 1330 Break
Afternoon Session: Chair - Dr Fiona Jenkinson, Newcastle upon Tyne Hospitals
1330 – 1400 Screening for lysosomal acid lipase deficiency in dried blood spots
Dr Marianne Barr, Queen Elizabeth University Hospital, Glasgow
1400 – 1430 Non-cholesterol sterols in hyperlipidaemia and metabolic disease
Dr Ann Bowron, Newcastle upon Tyne Hospitals
1430 – 1450 An inherited cause of paediatric dyslipidaemia and hepatomegaly
Dr Chris Stockdale, Newcastle upon Tyne Hospitals
1450 – 1500 Break
1500 – 1530 Next generation sequencing in the investigation of familial chylomicronaemia syndrome
Dr Paul Downie, Salisbury District Hospital and Bristol Royal Infirmary
1530 - 1600 Lipoprotein (a): When and how to measure it
Dr Dermot Neely, Newcastle upon Tyne Hospitals
1600 Close
Free for ACB members, £10 for non-members
This meeting is sponsored by Sanofi, Roche and Amgen
who have had no input into the content or organisation of this meeting